中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Version)
2015年
5期
693-695
,共3页
干扰素%肝炎,丙型,慢性%疗效
榦擾素%肝炎,丙型,慢性%療效
간우소%간염,병형,만성%료효
Interferon%Chronic hepatitis C%Effect
目的 分析不同干扰素药物治疗慢性丙型肝炎的近期疗效.方法 选择2009年8月至2014年8月于本院就诊的慢性丙型肝炎患者共80例,随机分为研究组(40例)和对照组(40例).研究组患者给予PegIFN-α-2a治疗,对照组患者给予IFN-α-2b治疗.治疗前进行HCV、抗-HCV、RNA定量、肝功能和血常规指标检测.治疗后对患者的血常规、尿素氮、肌酐、尿常规、甲状腺功能以及心电图复查.治疗4、12、24周分别监测两组患者的HCV RNA定量.记录治疗期间患者不良情况的发生率.结果 治疗第4、12、24周时,两组患者的外周静脉血HCV载量、AST以及ALT水平均较治疗前有显著下降,差异具有统计学意义(第4周:t = 2.012、P = 0.046,t = 2.351、P = 0.025;t = 2.757、P = 0.009;第12周:t= 2.181、P = 0.039,t = 2.334、P = 0.027,t = 2.351、P = 0.025;第24周:t = 2.811、P = 0.007,t = 3.012、P = 0.005,t = 3.527、P= 0.002).治疗第4周时,研究组患者治疗HCV病毒载量较对照组低,差异具有统计学意义(t = 2.233、P = 0.036);研究组患者的RVR显著优于对照组患者,差异具有统计学意义(χ2 = 3.982、P = 0.023).结论 PegIFN-α-2a治疗的RVR高于IFN-α-2b,但是两种方法的ETR、生物化学应答率、EVR以及不良反应发生率差异并无统计学意义.
目的 分析不同榦擾素藥物治療慢性丙型肝炎的近期療效.方法 選擇2009年8月至2014年8月于本院就診的慢性丙型肝炎患者共80例,隨機分為研究組(40例)和對照組(40例).研究組患者給予PegIFN-α-2a治療,對照組患者給予IFN-α-2b治療.治療前進行HCV、抗-HCV、RNA定量、肝功能和血常規指標檢測.治療後對患者的血常規、尿素氮、肌酐、尿常規、甲狀腺功能以及心電圖複查.治療4、12、24週分彆鑑測兩組患者的HCV RNA定量.記錄治療期間患者不良情況的髮生率.結果 治療第4、12、24週時,兩組患者的外週靜脈血HCV載量、AST以及ALT水平均較治療前有顯著下降,差異具有統計學意義(第4週:t = 2.012、P = 0.046,t = 2.351、P = 0.025;t = 2.757、P = 0.009;第12週:t= 2.181、P = 0.039,t = 2.334、P = 0.027,t = 2.351、P = 0.025;第24週:t = 2.811、P = 0.007,t = 3.012、P = 0.005,t = 3.527、P= 0.002).治療第4週時,研究組患者治療HCV病毒載量較對照組低,差異具有統計學意義(t = 2.233、P = 0.036);研究組患者的RVR顯著優于對照組患者,差異具有統計學意義(χ2 = 3.982、P = 0.023).結論 PegIFN-α-2a治療的RVR高于IFN-α-2b,但是兩種方法的ETR、生物化學應答率、EVR以及不良反應髮生率差異併無統計學意義.
목적 분석불동간우소약물치료만성병형간염적근기료효.방법 선택2009년8월지2014년8월우본원취진적만성병형간염환자공80례,수궤분위연구조(40례)화대조조(40례).연구조환자급여PegIFN-α-2a치료,대조조환자급여IFN-α-2b치료.치료전진행HCV、항-HCV、RNA정량、간공능화혈상규지표검측.치료후대환자적혈상규、뇨소담、기항、뇨상규、갑상선공능이급심전도복사.치료4、12、24주분별감측량조환자적HCV RNA정량.기록치료기간환자불량정황적발생솔.결과 치료제4、12、24주시,량조환자적외주정맥혈HCV재량、AST이급ALT수평균교치료전유현저하강,차이구유통계학의의(제4주:t = 2.012、P = 0.046,t = 2.351、P = 0.025;t = 2.757、P = 0.009;제12주:t= 2.181、P = 0.039,t = 2.334、P = 0.027,t = 2.351、P = 0.025;제24주:t = 2.811、P = 0.007,t = 3.012、P = 0.005,t = 3.527、P= 0.002).치료제4주시,연구조환자치료HCV병독재량교대조조저,차이구유통계학의의(t = 2.233、P = 0.036);연구조환자적RVR현저우우대조조환자,차이구유통계학의의(χ2 = 3.982、P = 0.023).결론 PegIFN-α-2a치료적RVR고우IFN-α-2b,단시량충방법적ETR、생물화학응답솔、EVR이급불량반응발생솔차이병무통계학의의.
Objective To analyze the short-time effect of different drugs on patients with chronic hepatitis C.Methods Total of 80 patients with chronic hepatitis C were selected in our hospital from August 2009 to August 2014. All patients were randomly divided into study group (40 cases) and control group (40 cases). Patients in study group's received PegIFN-α-2a therapy while the control group treated with IFN-α-2b. Before treatment, the levels of HCV, anti-HCV, quantitative detection of RNA, liver function and blood routine index were detected. After the treatment, blood routine, blood urea nitrogen, creatinine, urine routine, thyroid function of patients were reviewed, respctively. After 4, 12 and 24 weeks, HCV RNA quantitative were monitor of patients in two groups. The incidence of adverse events during the treatment period was recorded.Results At the treatment of 4, 12 and 24 weeks, patients in the two groups with peripheral venous blood HCV load, AST and the amount of ALT were all signiifcantly decreased, with signiifcant differences (The fourth week:t = 2.012, P = 0.046;t = 2.351, P = 0.025; t = 2.757,P = 0.009. Twelfth weeks: t = 2.181, P = 0.039;t = 2.334,P = 0.027; t = 2.351, P = 0.025; Twenty-fourth weeks:t = 2.811,P = 0.007;t = 3.012,P = 0.005;t= 3.527,P = 0.002). After 4 weeks, HCV viral load of patients in study group was lower than that in control group, with signiifcance difference (t = 2.233, P= 0.036). RVR of patients in the study group's was signiifcantly better than that the patients in the control group, with signiifcance difference (t= 2.233,P= 0.036). Conclusions PegIFN-α-2a treatment of RVR is higher than IFN-α-2b, but the levels of ETR, biochemical response rate, EVR and the incidence of adverse reactions after treated with the two methods were with no signiifcant differences.
